Pay in 4 interest-free payments of $12.25 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
BGJ-398 shows a rapid distribution from the vascular compartment into the peripheral tissues
which is 10-fold higher than peak tumor concentration
Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors
InChiKey: ZCDBTQNFAPKACC-UHFFFAOYSA-N
CC1C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)C=1)/C(/C)=C/[C@H]1C[C@@H](OC)[C@H](O)CC1 |c:46|
JNK-IN-8 - CAS# 1410880-22-6 60136 BGJ-398 shows a rapid distributionJNK IN 8, also known as JNK Inhibitor XVI, CAS No. 1410880 22 6, is a selective JNK inhibitor that inhibits phosphorylation of c Jun, a direct substrate of JNK, in cells exposed to submicromolar drug in a manner that depends on covalent modification of the conserved cysteine residue. Extensive biochemical, cellular, and pathway based profiling establish the selectivity of JNK IN 8 for JNK and suggests that the compound will be broadly useful as a
US$ 362.17
US$ 203.38
US$ 54.95
US$ 14.95
US$ 2860.18
US$ 24.95
US$ 995.00
US$ 14.95